title: A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys.
abstract: A DNA vaccine that expresses the premembrane/membrane (prM) and envelope (E) genes of dengue virus serotype-1 was tested for immunogenicity and protection against dengue-1 virus challenge in Aotus nancymae monkeys. The vaccine, in 1 mg doses, was administered intradermally (i.d.) to three monkeys and intramuscularly (i.m.) to three others. For controls, a 1 mg dose of vector DNA was administered i.d. to two monkeys and i.m. to one. All animals were primed and then boosted at one and five months post priming. Sera were collected monthly and analyzed for dengue-1 antibodies by enzyme linked immunosorbent assay (ELISA) and plaque reduction neutralization test (PRNT). Dengue-1 antibodies were detectable in the sera from i.d. and i.m. vaccine inoculated animals one month after the first boost and peaked one month after the second boost. The antibody levels from sera of animals that received the vaccine via the i.d. route were twice those from sera of animals that received the vaccine via the i.m. route. Six months after the second boost all inoculated and two naive monkeys were challenged with 1.25x10(4) plaque forming units (PFU) of dengue-1 virus. Two vaccine immunized animals were protected from viremia while the others showed a reduction in viremia. The mean days of viremia were 1 and 1.3 for the animals that were immunized with the vaccine via the i.d. or i.m. route, respectively vs 4 and 2 mean days of viremia in the animals inoculated with control DNA. Naive animals were viremic for an average of 4 days. All of the three control monkeys that received control DNA inoculum by either the i.d. or i.m. route had an intermittent viremia pattern with one or more negative days interspersed between the positive days. This pattern was not observed in any of the vaccine recipients or the naïve control monkeys. These results demonstrate that DNA immunization is a promising approach for the development of dengue vaccines and that A. nancymae monkeys are suitable for dengue vaccine trials.
authors.affiliation: Virology Program, Naval Medical Research Center, 8901 Wisconsin Avenue, 20889-5607, Bethesda, MD, USA. kochel@namrid.sld.pe
authors.forename: T J
authors.initials: TJ
authors.lastname: Kochel
authors.forename: K
authors.initials: K
authors.lastname: Raviprakash
authors.forename: C G
authors.initials: CG
authors.lastname: Hayes
authors.forename: D M
authors.initials: DM
authors.lastname: Watts
authors.forename: K L
authors.initials: KL
authors.lastname: Russell
authors.forename: A S
authors.initials: AS
authors.lastname: Gozalo
authors.forename: I A
authors.initials: IA
authors.lastname: Phillips
authors.forename: D F
authors.initials: DF
authors.lastname: Ewing
authors.forename: G S
authors.initials: GS
authors.lastname: Murphy
authors.forename: K R
authors.initials: KR
authors.lastname: Porter
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D001029:Aotus trivirgatus; D003715:Dengue / Q000517:prevention & control*; D003716:Dengue Virus / Q000276:immunology*; D005260:Female; D008297:Male; D012703:Serotyping; D019444:Vaccines, DNA / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D019444:Vaccines, DNA; D014765:Viral Vaccines